Gf Fund Management Co. Ltd. Corvus Pharmaceuticals, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $4.26 Trillion
- Q1 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,594 shares of CRVS stock, worth $6,312. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,594
Previous 1,349
18.16%
Holding current value
$6,312
Previous $7.22 Million
29.76%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRVS
# of Institutions
105Shares Held
36.7MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$27.5 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$16.1 Million0.21% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$13 Million10.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$11 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$10.6 Million0.14% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $184M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...